Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.33 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130995 | 0.91 | NAMPT (0.36) | TAS2R14NAMPTPTGER2 | |
| SCHEMBL4126098 | 0.91 | NAMPT (0.39) | NAMPTKEAP1NFE2L2HTTGPBAR1 | |
| SCHEMBL4135426 | 0.90 | NAMPT (0.36) | TAS2R14NAMPTKEAP1NFE2L2PTGER2 | |
| SCHEMBL4119622 | 0.89 | RIPK1 (0.36) | RIPK1NAMPTMDM2HTTGPBAR1 | |
| SCHEMBL4566347 | 0.88 | HTR2C (0.39) | PTGER2HTTGPBAR1KAT5KAT8 | |
| SCHEMBL4126504 | 0.88 | ALDH1A1 (0.39) | RIPK1MDM2HTTNOTUMKDM4E | |
| SCHEMBL4131429 | 0.88 | KEAP1 (0.36) | TAS2R14NAMPTKEAP1NFE2L2PTGER2 | |
| SCHEMBL4125804 | 0.88 | NAMPT (0.36) | TAS2R14NAMPTKEAP1NFE2L2PTGER2 | |
| SCHEMBL4566348 | 0.88 | PTGER2 (0.33) | TAS2R14RIPK1PTGER2HTT | |
| SCHEMBL4131198 | 0.87 | NAMPT (0.39) | TAS2R14NAMPTPTGER2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | TAS2R14 329/4885RIPK1 4203/4885NAMPT 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.